Key result
Regional and remote residence shows no difference in 12-month post-TAVR mortality compared with urban residence.
Why the study?
TAVR can only be performed at centres meeting strict regulatory requirements. It remained unclear whether this requirement restricts TAVR access for patients in rural Australia and results in poorer outcomes compared with metropolitan counterparts.
Does residing in regional or remote areas affect 12-month mortality compared to urban areas in Queensland patients undergoing TAVR?
Cohort (n=6,813)
Yes
Does residing in regional or remote areas affect 12-month mortality compared to urban areas in Queensland patients undergoing TAVR?
Twelve-month mortality following TAVR in Queensland is comparable across urban, regional, and remote patients, supporting the equity of outcomes within a centralized TAVR delivery model for patients who reach the procedure.
Answers are grounded in this paper and cite their sources.
No mortality difference by rurality in TAVR recipients supports outcome equity; leaves open whether remote access barriers affect procedure utilization.
Background Transcatheter aortic valve replacement (TAVR) offers a minimally invasive approach to treat severe aortic stenosis (AS) but can only be performed at centres meeting strict regulatory requirements. It remains unclear whether this requirement restricts TAVR access for patients residing in rural Australia, and whether such people experience poorer outcomes than metropolitan counterparts as a result. Methods This multicentre retrospective cohort study used Australian Cardiac Outcomes Registry data. All Queensland residents who underwent TAVR between April 2018 and 27 March 2026 were included. Rurality was assigned by postcode using the Modified Monash Model (MMM) and grouped as urban (MMM1), regional (MMM2-4), or remote (MMM5-7). The primary outcome was 12-month mortality and was investigated using Kaplan-Meier and Cox proportional hazards analyses. Findings Among 6813 patients, 4246 (62%) were urban, 2092 (31%) regional, and 475 (7%) remote. Twelve-month all-cause mortality did not differ by rurality (urban: 211 [5.0%]; regional: 103 [4.9%]; remote: 23 [4.8%]; χ 2 =0.991, log-rank P=0.929), a finding confirmed in multivariable analysis. At the time of TAVR, regional and remote patients were younger, more comorbid, had more severe AS, and lower STS scores than urban counterparts. Clinical frailty score, non-transfemoral access, STS score, atrial fibrillation or flutter, and moderate-severe chronic lung disease independently predicted 12-month mortality. Interpretation TAVR outcomes were comparable between rurality groups, suggesting equitable care within Queensland's centralised TAVR model. However, registry data only captures patients who underwent TAVR and may miss older rural patients facing barriers to AS diagnosis, referral, or procedural workup. Funding There was no funding or sponsor involvement.
No takes yet. Share an insight, caveat, or question.
Cameron et al. (2026) conducted a cohort in Severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR) (n=6,813). Regional (MMM2-4) or remote (MMM5-7) residence vs. Urban residence (MMM1) was evaluated on 12-month all-cause mortality (p=0.929). Regional (4.9%) and remote (4.8%) residence had similar 12-month mortality after TAVR compared with urban residence (5.0%; log-rank P=0.929).
Synapse has enriched 10 related papers. Consider them for comparative context: